[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366455-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366455-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-application-of-organoids-in-treatment-decision-making-for-digestive-system-cancers-progress-and-challenges","The application of organoids in treatment decision-making for digestive system cancers - progress and challenges","","Digestive system cancers—including gastric, liver, colorectal, esophageal, and pancreatic malignancies—remain leading causes of cancer death, with treatment resistance posing major challenges in advanced disease. Patient-derived cancer organoids (PDCOs), 3D mini-tumors grown from patient biopsies, have revolutionized personalized oncology by faithfully replicating tumor biology and enabling predictive drug testing across chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Limitations include incomplete tumor microenvironments, variable establishment rates, and lengthy processing times. Emerging AI, organ-on-chip, and 3D bioprinting help address these issues while clinical trials evaluate neoadjuvant and real-time guidance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-application-of-organoids-in-treatment-decision-making-for-digestive-system-cancers-progress-and-challenges/366455/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-application-of-organoids-in-treatment-decision-making-for-digestive-system-cancers-progress-and-challenges/366455.png","ImageObject",300,407,{"name":42,"@type":43},"McGucket","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are patient-derived cancer organoids (PDCOs) and how are they used in treatment decision-making?","Question",{"text":63,"@type":64},"PDCOs are 3D mini-tumors grown from patient biopsies that replicate tumor biology. They enable predictive drug testing to guide chemotherapy, radiotherapy, targeted therapy, and immunotherapy decisions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations currently affect PDCO-based predictions?",{"text":68,"@type":64},"Key limitations include incomplete tumor microenvironments, variable establishment rates, and lengthy processing times, which can reduce consistency and speed of decision support.",{"name":70,"@type":61,"acceptedAnswer":71},"How are emerging technologies expected to improve PDCO workflows or predictive power?",{"text":72,"@type":64},"AI, organ-on-chip systems, and 3D bioprinting are highlighted as approaches to address microenvironment gaps and other practical challenges, supporting broader and more reliable clinical use.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366455,1790196553,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Wang et al. Molecular Cancer (2025) 24:222 Molecular Cancer  \n[https://doi.org/10.1186/s12943-025-02429-0](https://doi.org/10.1186/s12943-025-02429-0)  \nREVIEW Open Access  \nThe application of organoids in treatment decision-making for digestive system cancers:  \nprogress and challenges  \nYufei Wang 1†, Limin Zhang2,3†, Louis Zizhao Wang4,5†, Yang Cao6,7, Lulu Huang6,8, Gautam Sethi9,10, Xiaoguang Chen 1*, Lingzhi Wang6,9,10* and Boon-Cher Goh6,9,10,11*  \nAbstract  \nDigestive system cancers—including gastric, liver, colorectal, esophageal, and pancreatic malignancies—remain leading causes of cancer death, with treatment resistance posing major challenges in advanced disease. Patientderived cancer organoids (PDCOs), 3D mini-tumors grown from patient biopsies, have revolutionized personalized oncology by faithfully replicating tumor biology and enabling predictive drug testing for chemotherapy, radiotherapy, targeted therapy, and immunotherapy. While demonstrating good predictive accuracy, current limitations include incomplete tumor microenvironments, variable establishment rates, and lengthy processing times. Emerging technologies like AI, organ-on-chip systems, and 3D bioprinting are addressing these challenges, while clinical trials explore applications in neoadjuvant therapy and real-time treatment guidance. This Review highlights key advances in PDCO technology and its transformative potential for treatment decision-making in digestive system cancers, bridging laboratory research with clinical care to enable truly personalized therapeutic strategies tailored to individual tumor biology.  \nKeywords Digestive system cancers, Organoids, Tumor microenvironment, Drug screening, Precision oncology, Personalized medicine  \n†Yufei Wang, Limin Zhang and Louis Zizhao Wang contributed equally to this work.  \n*Correspondence: Xiaoguang Chen[chen_xg@yangtzeu.edu.cn](chen_xg@yangtzeu.edu.cn)[ ](chen_xg@yangtzeu.edu.cn)Lingzhi Wang [csiwl@nus.edu.sg](csiwl@nus.edu.sg)  \nBoon-Cher Goh [phcgbc@nus.edu.sg](phcgbc@nus.edu.sg)  \n1School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou 434023, China  \n2Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou 434000, China  \n3The Third Clinical Medical College of Yangtze University, Jingzhou 434000, China  \n4Department of Gastroenterology & Hepatology, Changi General Hospital, Singapore 529889, Singapore  \n5Singhealth Duke-NUS Academic Medical Centre, Singapore  \n168582, Singapore  \n6Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore  \n7Department of Laboratory Medicine, The First Hospital of Jilin University, Jilin 130031, China  \n8Department of Radiation Oncology, First Affiliated Hospital of Guangxi Medical University, Shuang Yong Road 22, Nanning, Guangxi  \n530021, China  \n9Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore  \n10Yong Loo Lin School of Medicine, NUS Center for Cancer Research (N2CR), National University of Singapore, Singapore 117599, Singapore 11Department of Haematology-Oncology, National University Cancer Institute, Singapore 119228, Singapore  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and yo","cbCaiuv8Aq8dbVsi","https://ap.wps.com/l/cbCaiuv8Aq8dbVsi","pdf",2844675,25,"English","# Abstract\n## Introduction\n## Review: applications of PDCOs in treatment decision-making\n## Challenges and limitations\n## Emerging technologies and clinical translation","[{\"question\":\"What are patient-derived cancer organoids (PDCOs) and how are they used in treatment decision-making?\",\"answer\":\"PDCOs are 3D mini-tumors grown from patient biopsies that replicate tumor biology. They enable predictive drug testing to guide chemotherapy, radiotherapy, targeted therapy, and immunotherapy decisions.\"},{\"question\":\"What limitations currently affect PDCO-based predictions?\",\"answer\":\"Key limitations include incomplete tumor microenvironments, variable establishment rates, and lengthy processing times, which can reduce consistency and speed of decision support.\"},{\"question\":\"How are emerging technologies expected to improve PDCO workflows or predictive power?\",\"answer\":\"AI, organ-on-chip systems, and 3D bioprinting are highlighted as approaches to address microenvironment gaps and other practical challenges, supporting broader and more reliable clinical use.\"}]","The application of organoids in treatment decision-making for digestive system cancers - progress and challenges | PDF",1790165643,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00e450b8eb824d869da6f2d79afd2921.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc9a3ab4a3f5df3e49d4803292b342a0.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0560711879e89648179df2178d10d970.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c197e0c35c44fd3003e1f54b0f7f819f.webp",980,1306]